<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PINDOLOL</span><br/>(pin'doe-lole)<br/><span class="topboxtradename">Visken<br/></span><b>Classifications:</b> <span class="classification">beta-adrenergic antagonist (blocking agent)</span>; <span class="classification">sympatholytic</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonselective beta-adrenergic blocking agent. Possesses slight intrinsic sympathomimetic activity (ISA) or partial beta agonist
         effect in therapeutic dose ranges. Hypotensive mechanism is similar to that of propranolol. It competitively blocks beta-adrenergic
         receptors primarily in myocardium, and beta receptors within bronchial and smooth muscle.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Exerts vasodilator as well as hypotensive effects. Has negative chronotropic and inotropic properties and slows conduction
         in AV node. Does not consistently affect cardiac output, resting heart rate, or renin release; it does, however, decrease
         peripheral vascular resistance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of hypertension concurrently with a thiazide diuretic or as single agent. Used in patient who has failed to respond
         to diet, exercise, and weight reduction.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Stress and exercise-induced chronic stable angina pectoris.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Bronchospastic diseases; severe bradycardia, cardiogenic shock, cardiac failure. Safety in pregnancy (category B), lactation,
         or children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Nonallergic bronchospasm; CHF; diabetes mellitus; hyperthyroidism; impaired liver and kidney function.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg b.i.d., may increase by 10 mg/d q23wk if needed up (max: 60 mg/d in 23 divided doses)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 5 mg q.d.<br/><br/><span class="indicationtitle">Angina Pectoris</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1540 mg/d in 34 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug at same time of day each day with respect to time of food intake for most predictable results.</li>
<li>Withdraw or discontinue treatment gradually over a period of 12 wk.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Fatigue,</span> dizziness, insomnia, drowsiness, confusion, fainting, decreased libido. <span class="typehead">CV:</span> <span class="speceff-common">Bradycardia,</span> hypotension, CHF. <span class="typehead">GI:</span> Nausea, <span class="speceff-common">diarrhea, constipation,</span> flatulence. <span class="typehead">Respiratory:</span> <span class="speceff-life">Bronchospasm</span>, pulmonary edema, dyspnea. <span class="typehead">Body as a Whole:</span> Back or joint pain. Sensitivity reactions seen as antinuclear antibodies (ANA) (1030% of patients). <span class="typehead">Hematologic:</span> <span class="speceff-life">Agranulocytosis</span>. <span class="typehead">Urogenital:</span> Impotence. <span class="typehead">Metabolic:</span> Hypoglycemia (may mask symptoms of a hypoglycemic reaction). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">diuretics</span> and other <span class="classification">hypotensive agents</span> increase hypotensive effect; effects of <b>albuterol,</b> <b>metaproterenol,</b> <b>terbutaline,</b> <b>pirbuterol</b> and pindolol antagonized; <span class="classification">nsaid</span>s blunt hypotensive effect; decreases hypoglycemic effect of <b>glyburide;</b> <b>amiodarone</b> increases risk of bradycardia and sinus arrest. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 5095% reaches systemic circulation (first pass metabolism). <span class="typehead">Onset:</span> 3 h. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> 4060% metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor HR and BP. Report bradycardia and hypotension. Dosage adjustment may be indicated.</li>
<li> 							Note: Hypotensive effect may begin within 7 d but is not at maximum therapeutically until about 2 wk after beginning of treatment. 						</li>
<li>Lab test: Periodic CBC with differential, kidney function tests, and blood glucose.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Pindolol masks the dizziness and sweating symptoms of hypoglycemia. Monitor blood glucose for loss of glycemic control.</li>
<li>Adhere to the prescribed drug regimen; if a change is desired, consult physician first. Abrupt withdrawal of drug might precipitate
            a thyroid crisis in a patient with hyperthyroidism, and angina in the patient with ischemic heart disease, leading to an MI.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>